logo
Plus   Neg
Share
Email

Jazz Pharma Submits MAA To European Medicines Agency For Solriamfetol

Jazz Pharmaceuticals plc (JAZZ) announced Friday the submission of a Marketing Authorization Application or MAA to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. It is for the treatment to improve wakefulness and reduce excessive daytime sleepiness or EDS in adult patients with narcolepsy (with or without cataplexy) or obstructive sleep apnea or OSA.

Jazz said it has studied solriamfetol extensively via the Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES) Phase 3 program, which was comprised of four studies.

Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of EDS in adult patients with narcolepsy, OSA, and Parkinson's disease. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize solriamfetol from Aerial Biopharma.

Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China and Japan.

Solriamfetol has orphan drug designation in the United States for narcolepsy. In March 2018, Jazz announced that the U.S. Food and Drug Administration accepted for filing with standard review the company's New Drug Application or NDA seeking marketing approval for solriamfetol for the treatment of ES in adult patients with narcolepsy or OSA. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is December 20, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of... Chipmaker Intel Corp. said it plans to exit the 5G smartphone modem business, with the announcement coming just hours after Apple Inc. and Qualcomm Inc. said they have settled their royalty dispute. The settlement includes a payment from Apple to Qualcomm, but no details were disclosed about the payment or fees. Qualcomm's shares are gaining more than 14 percent in Wednesday's trading session.
Follow RTT